about
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancerEffect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study.Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
P50
Q35764604-AB2B71B5-41CE-4FA2-B924-7E27366ADDC7Q36029360-3C0B079A-42B4-4948-BDCB-B01224148A0EQ36184256-46D8E3E6-E68F-4781-AACE-19A44D9B5467Q37136423-4ACDB780-698C-44DE-82A0-097F1790FF0FQ42482401-AB7F44E3-467D-4CEC-9260-C1BE0A9E3050Q43060378-B51E603E-2435-44D1-AFAA-5EBCE65FEF2EQ54654985-DC4B6199-DF5E-4020-9915-D3EDB8F0C57BQ55068564-64D2BFB1-D6D9-43DF-A057-41C913D3C5AA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alessandra Fabi
@ast
Alessandra Fabi
@en
Alessandra Fabi
@es
Alessandra Fabi
@nl
type
label
Alessandra Fabi
@ast
Alessandra Fabi
@en
Alessandra Fabi
@es
Alessandra Fabi
@nl
prefLabel
Alessandra Fabi
@ast
Alessandra Fabi
@en
Alessandra Fabi
@es
Alessandra Fabi
@nl
P106
P1153
35509014100
P31
P496
0000-0002-0758-8033